(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.75%.
IMMIX Biopharma's earnings in 2026 is -$39,917,211.On average, 10 Wall Street analysts forecast IMMX's earnings for 2026 to be -$51,465,382, with the lowest IMMX earnings forecast at -$60,994,419, and the highest IMMX earnings forecast at -$42,816,279. On average, 9 Wall Street analysts forecast IMMX's earnings for 2027 to be -$59,835,482, with the lowest IMMX earnings forecast at -$100,255,195, and the highest IMMX earnings forecast at -$6,009,302.
In 2028, IMMX is forecast to generate -$19,794,928 in earnings, with the lowest earnings forecast at -$64,499,846 and the highest earnings forecast at $21,404,563.